Table 4 Measles and Rubella seroprevalence rates demonstrated in different studies before and after MR campaign in Iran
Author/province | Relation to 2003 MR campaign | Years of study | No of Subjects (Age-groups) | Tested method | Prevalence Rate | |
|---|---|---|---|---|---|---|
Measles | Rubella | |||||
Emami-Naeini, Shiraz [33] | Before 3-yr | 2000 | 241 (19–25 yr) | ELISA | 40.7% |  |
Yekta, Uremia [34] | Before (1- yr) | 2002 | 835 (5–25 yr) | ELISA | 54.7% | – |
Saffar, Sari [35] | Before (1- yr) | 2002 | 590(15–25 yr) | ELISA | 55.4% | – |
Zamani, Tehran [36] | Before (2- yr) | 2001 | 1665 (6-11 yr) | ELISA | 72% | – |
Salimi, Tabriz [37] | Before (1- yr) | 2002 | 225 (5–25 yr) | HI test | 91.6% | – |
Pourabbas, Shiraz [24] | After (1- yr) | 2004–5 | 909(6-26 yr) | ELISA | 80.6–87.5% | 91.0–99% |
Yekta, Uremia [25] | After (1- yr) | 2004 | 624 (6-25 yr) | ELISA | 72.3% | – |
Honarvar, Shiraz [26] | After (7- yr) | 2010–11 | 175 (16-24 yr) | ELISA | 81.7% | 96% |
Keshavarz, Tehran [27] | After (10- yr) | 2014 | 53 (19–26 yr) | ELISA | 79.2% | 96.2% |
Izadi, Bluchestan [28] | After (12–13- yr) | 2015 | 1056 (16–20 yr) | ELISA | 91.7% | 87.4% |
Karami, Hamadan [29] | After (13- yr) | 2016 | 272 (1–40 yr) | ELISA | 63.2% | – |